Biogen (XSWX:BIIB) Machinery, Furniture, Equipment : CHF0 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biogen Machinery, Furniture, Equipment?

Biogen's Machinery, Furniture, Equipment for the quarter that ended in Mar. 2024 was CHF0 Mil.

Biogen's quarterly Machinery, Furniture, Equipment increased from Sep. 2023 (CHF0 Mil) to Dec. 2023 (CHF2,419 Mil) but then declined from Dec. 2023 (CHF2,419 Mil) to Mar. 2024 (CHF0 Mil).

Biogen's annual Machinery, Furniture, Equipment increased from Dec. 2021 (CHF2,417 Mil) to Dec. 2022 (CHF2,490 Mil) but then declined from Dec. 2022 (CHF2,490 Mil) to Dec. 2023 (CHF2,419 Mil).

Biogen Machinery, Furniture, Equipment Historical Data

The historical data trend for Biogen's Machinery, Furniture, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Machinery, Furniture, Equipment Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Machinery, Furniture, Equipment

Get a 7-Day Free Trial

1,671.60

1,770.85

2,417.16

2,489.70

2,419.19

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Machinery, Furniture, Equipment	Get a 7-Day Free Trial															-	-	-	2,419.19	-

Biogen Machinery, Furniture, Equipment Calculation

Machinery, Furniture, Equipment represents those fixed assets specifically dealing with tools, equipment and office furniture.

Biogen (XSWX:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (XSWX:BIIB) » Definitions » Machinery, Furniture, Equipment

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.